Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients
- 29 May 2013
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 34 (5) , 2921-2927
Abstract
The aim of this study was to evaluate the diagnostic and potential prognostic value of cell-free plasma DNA (CF-pDNA) in patients with suspected or histologically proven prostate cancer (PCa). We included 133 men with a diagnosis of PCa and 33 controls. PCa patients had blood samples prospectively drawn every 3 months for 2 years. CF-pDNA was measured by spectrophotometry. Considering a cut-off value of 140 ng/mL of CF-pDNA the area under the curve was of 0.824(0.757–0.879 with a sensitivity = 66.2 % and a specificity = 87.9 %) and the positive and negative likelihood ratio were of 5.46 and 0.39, respectively. CF-pDNA tends to decrease slightly and return to baseline values in about a week after biopsy. There was no statistical significant correlation between CF-pDNA levels at study entry with PSA, Gleason score, stage and biochemical recurrence free survival (BRFS). However, with a mean follow-up of 13.5 months, we could observe a significant shorter BRFS for patients with at least one value above 140 ng/mL of CF-pDNA during follow-up (p = 0.048). CF-pDNA is a potentially valuable biomarker for PCa diagnosis and a potential tool for the follow-up of patients with PCa.Keywords
This publication has 24 references indexed in Scilit:
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised DiseaseEuropean Urology, 2011
- A systematic review of the diagnostic accuracy of prostate specific antigenBMC Urology, 2009
- Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate CancerClinical Cancer Research, 2009
- Cell-Free Circulating DNA: Diagnostic Value in Patients With Testicular Germ Cell CancerJournal of Urology, 2009
- Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicatorsInternational Journal of Cancer, 2007
- Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical ProstatectomyClinical Cancer Research, 2007
- Circulating tumour‐associated plasma DNA represents an independent and informative predictor of prostate cancerBJU International, 2006
- Increased Integrity of Free Circulating DNA in Sera of Patients with Colorectal or Periampullary Cancer: Direct Quantitative PCR for ALU RepeatsClinical Chemistry, 2006
- Prospective Study of Quantitation of Plasma DNA Levels in the Diagnosis of Malignant versus Benign Prostate DiseaseClinical Cancer Research, 2005
- Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancerCancer Letters, 2004